urgent
need
new
strategi
combat
hundr
human
diseasecaus
intracellular
pathogen
includ
virus
intracellular
bacteria
protozoa
current
approv
antivir
drug
treat
fewer
ten
viral
infect
antibacteri
agent
wide
avail
minor
penetr
mammalian
cell
achiev
therapeut
level
appropri
intracellular
compart
treat
intracellular
bacteri
narrow
spectrum
coverag
antimicrobi
target
microbi
function
particularli
virus
anoth
major
limit
given
high
averag
cost
two
billion
dollar
long
timelin
year
develop
new
drug
scalabl
target
microb
individu
limit
lastli
resist
typic
emerg
rapidli
convent
drug
target
microbi
function
use
monotherapi
attract
solut
overcom
limit
repurpos
alreadi
approv
drug
target
host
function
requir
lifecycl
intracellular
pathogen
antimicrobi
agent
figur
offlabel
use
approv
drug
requir
significantli
less
capit
time
diminish
clinic
risk
drug
alreadi
rigor
test
toxic
pharmacokinet
pharmacodynam
dose
etc
primari
indic
sinc
host
function
hijack
variou
virus
intracellular
bacteria
andor
protozoa
may
repres
target
broadspectrum
antimicrobi
approach
therefor
increas
effici
antimicrobi
develop
improv
drug
access
patient
facilit
readi
futur
outbreak
emerg
pathogen
addit
hosttarget
approach
may
ad
benefit
higher
genet
barrier
emerg
resist
one
promis
drug
categori
repurpos
antimicrobi
inhibitor
host
kinas
wide
approv
treatment
cancer
inflammatori
larg
number
host
kinas
coopt
intracellular
pathogen
thu
repres
attract
target
broadspectrum
antimicrobi
inde
recent
effort
demonstr
therapeut
potenti
kinas
inhibitor
combat
variou
intracellular
microbi
infect
anticanc
epiderm
growth
factor
receptor
egfr
andor
kinas
inhibitor
gefitinib
erlotinib
lapatinib
demonstr
vitro
activ
number
virus
includ
hepat
c
viru
hcv
human
cytomegaloviru
hcmv
gefitinib
lapatinib
also
inhibit
hcv
hcmv
infect
mous
guinea
pig
model
reduc
replic
mycobacterium
tuberculosi
mtb
lung
infect
antivir
effect
drug
mediat
part
inhibit
signal
entri
stage
andor
factinmedi
intracellular
viral
enhanc
antimicrobi
immun
effect
via
inhibit
mitogen
associ
protein
kinas
signal
play
role
antimtb
anoth
class
approv
kinas
inhibitor
demonstr
broad
antimicrobi
coverag
cellular
abelson
tyrosin
kinas
cabl
inhibitor
imatinib
nilotinib
drug
inhibit
replic
ebola
viru
ebov
dengu
viru
denv
middl
eastern
respiratori
syndrom
coronaviru
merscov
sever
acut
respiratori
syndrom
coronaviru
sarscov
cultur
cell
reduc
vaccinia
viru
load
spread
overal
mortal
mous
moreov
imatinib
treatment
impair
entri
intracellular
surviv
mtb
mycobacterium
marinum
infect
macrophag
reduc
bacteri
load
associ
patholog
mice
infect
antibioticsensit
resist
notabl
coadminist
rifamycin
imatinib
display
synergi
indic
potenti
util
combin
antimtb
drug
molecular
target
underli
antimicrobi
effect
cabl
inhibitor
remain
valid
moreov
inhibit
actin
motil
propos
mechan
antivir
action
precis
mechan
mode
antibacteri
action
remain
unknown
approv
anticanc
drug
sunitinib
erlotinib
display
potent
activ
virus
six
viral
famili
includ
denv
ebov
cultur
combin
drug
reduc
morbid
mortal
dengu
ebola
infect
mice
advanc
clinic
studi
dengu
possibl
ebola
futur
outbreak
http
clinicaltrialsgov
inhibit
cellular
kinas
adaptor
protein
associ
protein
kinas
cyclin
gassoci
kinas
gak
regul
adaptor
proteinmedi
intracellular
viral
traffick
import
mechan
action
moa
antivir
three
approv
immunosuppress
drug
inhibit
phosphatidylinositol
target
rapamycin
pathway
leflunomid
everolimu
sirolimu
reduc
viremia
nephropathi
progress
patient
infect
bk
viru
member
polyomaviru
famili
use
individu
addit
leflunomid
demonstr
activ
hcmv
vitro
rat
direct
suppress
viral
replic
propos
one
underli
mechan
approach
precis
moa
molecular
target
remain
unknown
inhibitor
cyclophilin
host
factor
facilit
protein
fold
repres
anoth
class
drug
beyond
kinas
inhibitor
show
promis
antimicrobi
cyclosporin
immunosuppress
cyclophilin
inhibitor
disrupt
replic
multipl
virus
includ
hcv
denv
flavivirus
human
immunodefici
viru
hiv
two
experiment
nonimmunosuppress
cyclophilin
inhibitor
alisporivir
also
inhibit
multipl
rna
virus
cultur
cell
yet
effect
mous
model
alisporivir
significantli
reduc
hcv
viral
load
chronic
infect
patient
howev
clinic
hold
place
phase
iii
trial
due
toxic
cyclosporin
also
inhibit
erythrocyt
stage
plasmodium
falciparum
vitro
rodent
malaria
mous
nevertheless
remain
unknown
whether
effect
result
part
inhibit
host
cyclophilin
sole
parasit
protein
anoth
candid
repurpos
nitazoxanid
drug
approv
treatment
parasiteinduc
diarrhea
inhibit
replic
multipl
virus
includ
hcv
flavivirus
respiratori
virus
hiv
hepat
b
viru
hbv
cultur
nitazoxanid
block
matur
influenza
hemagglutinin
target
remain
unknown
case
hcv
thought
activ
protein
kinas
r
lead
phosphoryl
eukaryot
initi
factor
block
viral
phase
ii
trial
nitazoxanid
modestli
reduc
time
resolut
symptom
flu
current
evalu
phase
iii
trial
wherea
addit
nitazoxanid
peginterferonribavirin
improv
sustain
virolog
respons
hcv
patient
phase
ii
trial
improv
observ
phase
iii
trial
genotyp
infect
addit
nitazoxanid
effect
clinic
mtb
isol
includ
resist
standard
antituberculosi
disrupt
membran
potenti
ph
homeostasi
mtb
one
propos
phase
ii
clinic
trial
current
ongo
determin
efficaci
nitazoxanid
treatment
prior
initi
standard
antituberculosi
therapi
metformin
drug
approv
treatment
type
diabet
inhibit
intracellular
growth
mtb
includ
drug
resist
strain
enhanc
efficaci
approv
antimtb
drug
cell
murin
model
metformin
mildli
reduc
mtb
load
target
organ
improv
lung
patholog
use
individu
combin
drug
notabl
metformin
demonstr
efficaci
decreas
diseas
sever
improv
clinic
outcom
adjunct
therapi
retrospect
cohort
tuberculosi
patient
diabet
also
reduc
incid
latent
tuberculosi
diabet
activ
adenosin
protein
kinas
ampk
regul
cellular
immun
function
involv
mediat
antibacteri
beyond
tuberculosi
clinic
studi
aim
evalu
size
hiv
reservoir
upon
addit
metformin
antiretrovir
regimen
current
ongo
statin
drug
inhibit
coenzym
reductas
hmgcoar
repres
anoth
potenti
class
repurpos
hosttarget
antimicrobi
variou
statin
inhibit
replic
hcv
denv
nevertheless
sever
retrospect
studi
demonstr
statin
reduc
relaps
rate
patient
infect
hcv
ad
peginterferonribavirin
effect
quit
mechan
antihcv
action
statin
mediat
part
effect
lipid
biosynthesi
antivir
activ
cell
revers
upon
addit
mevalon
geranylgeraniol
resist
drug
coincid
increas
hmgcoar
due
abil
restor
endotheli
stabil
statin
also
propos
strategi
treat
infect
associ
endotheli
dysfunct
formal
studi
conduct
report
atorvastatin
combin
angiotensin
receptor
blocker
reduc
mortal
ebola
patient
sierra
antimalari
antiinflammatori
drug
chloroquin
also
show
promis
antimicrobi
agent
nonhuman
primat
dengu
model
chloroquin
reduc
viremia
cytokin
product
organ
howev
studi
dengu
patient
reduc
pain
improv
daili
activ
perform
yet
reduc
diseas
durat
mice
infect
zika
viru
chloroquin
increas
life
span
reduc
vertic
transmiss
fetal
brain
moreov
reduc
acut
lung
injuri
morbid
mortal
mous
model
avian
influenza
mechan
antivir
activ
chloroquin
multifacet
thought
involv
alter
intracellular
ph
caus
impair
fusion
cleavag
prm
protein
flavivir
releas
andor
inhibit
chloroquin
may
also
show
util
addon
antituberculosi
regimen
enhanc
intracellular
kill
mtb
human
macrophag
inhibit
breast
cancer
resist
mediat
activ
efflux
antituberculosi
drug
isoniazid
collect
data
provid
proofofconcept
use
expans
antimicrobi
drug
target
focus
host
function
therapeut
potenti
repurpos
drug
target
function
combat
intracellular
pathogen
benefit
provid
higher
genet
barrier
resist
associ
mani
hosttarget
approach
wherea
emerg
resist
complic
treatment
hosttarget
approach
case
chemokin
receptor
antagonist
time
resist
hosttarget
approach
longer
level
resist
lower
rel
typic
directact
antimicrobi
monotherapi
exemplifi
treatment
denv
sunitiniberlotinib
combin
mtb
nitazoxanid
hcv
cyclophilin
target
host
protein
genet
control
microb
simultan
inhibit
sever
host
target
drug
drug
combin
thought
facilit
increas
resist
barrier
approach
nevertheless
repurpos
hosttarget
drug
antimicrobi
face
challeng
cellular
protein
function
complex
network
interact
inhibitor
often
nonselect
thu
mechan
antimicrobi
action
hosttarget
approach
often
remain
elus
molecular
target
underli
effect
unvalid
exampl
erlotinib
effect
hcv
infect
first
attribut
sole
effect
egfr
cancer
target
yet
later
demonstr
inhibit
gak
anoth
target
inhibit
erlotinib
compar
potenc
egfr
also
play
drug
nitazoxanid
chloroquin
moa
even
less
clear
appear
pathogen
anoth
challeng
antimicrobi
effect
observ
vitro
often
reproduc
vivo
exampl
sever
multi
kinas
inhibitor
lestaurtinib
display
vitro
activ
plasmodium
falciparum
signific
effect
malariainfect
moreov
exemplifi
chloroquin
dengu
treatment
promis
effect
anim
model
guarante
effect
toxic
anoth
major
concern
src
cablinhibitor
dasatinib
demonstr
broadspectrum
antivir
activ
cultur
cell
yet
murin
model
vaccinia
viru
induc
immunosuppress
rather
thu
import
investig
antimicrobi
activ
safeti
drug
anim
model
infect
nevertheless
drug
may
feasibl
find
therapeut
window
drug
level
suffici
inhibit
microbi
replic
minim
cellular
toxic
shift
indic
requir
longterm
therapi
eg
month
year
cancer
shorter
durat
suffici
treat
acut
infect
help
limit
toxic
contrast
util
approach
treat
chronic
infect
requir
longer
durat
treatment
may
limit
exemplifi
unexpect
occurr
pancreat
phase
iii
trial
alisporivir
chronic
infect
hcv
patient
nevertheless
drug
extens
use
human
metformin
chloroquin
like
safe
addon
standard
regimen
even
chronic
infect
summari
exampl
provid
proofofconcept
potenti
feasibl
repurpos
approv
drug
hosttarget
broadspectrum
therapi
combat
intracellular
microbi
pathogen
effect
meet
clinic
need
pose
emerg
intracellular
pathogen
approach
may
find
util
combin
novel
hosttarget
approach
microbialtarget
strategi
